+145.3%
AEHR vs GSK
+14.9%
+130.4%
-64.7%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -6.6% | +5.0% | -11.6% | -4.1% |
| 7D | -5.7% | +4.9% | -10.7% | -3.2% |
| 30D | -41.7% | +9.9% | -51.6% | -39.0% |
| 3M | -44.6% | +0.2% | -44.8% | -42.9% |
| 6M | -28.9% | +2.3% | -31.3% | -27.2% |
| YTD | +201.3% | +7.1% | +194.3% | +217.8% |
| 1Y | +145.3% | +13.1% | +132.2% | +151.9% |
| All | +145.3% | +14.9% | +130.4% | +151.9% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling